Ruxolitinib attenuates microglial inflammatory response by inhibiting NF-κB/MAPK signaling pathway
European Journal of Pharmacology · 2024-04 · 968 · 176403
DOI: 10.1016/j.ejphar.2024.176403 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2024-04. Verfasst von Jingli Min und 6 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Yongkang First People's Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China. Hauptthemen laut MEDLINE: NF-kappa B, Microglia, Nitriles, Pyrazoles. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Abstract (Originalsprache)
Neuroinflammation is involved in the physiological and pathological processes of numerous neurological diseases, and its inhibition seems to be a promising therapeutic direction for these diseases. Ruxolitinib is a classical Janus kinase (JAK) inhibitor that is oral, highly potent and bioavailable, which has recently gained approval from the US Food and Drug Administration (FDA) for the treatment of inflammatory disorders. The potential inhibitory effect of ruxolitinib on neuroinflammation has not been fully studied. In the lipopolysaccharide (LPS) induced neuroinflammatory cell model, we observed that ruxolitinib reduced the levels of IL-1β, IL-6 and tumor necrosis factor-α (TNF-α) expression, and neuroinflammation by inhibiting the Mitogen-Activated Protein Kinase/Nuclear factor-κ B (MAPK/NF-κB) signaling pathway. Similarly, mice injected intracerebroventricular with ruxolitinib exhibited significantly reduced LPS-stimulated activation of microglia and astrocytes, and expression of proinflammatory cytokine IL-1β, TNF-α and IL-6. These results demonstrate that ruxolitinib attenuates the neuroinflammatory responses both in vivo and in vitro, at least in part by inhibiting MAPK/NF-κB signaling pathway. Our findings suggest that ruxolitinib may serve as a potential drug for the treatment of microglia-mediated neuroinflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Yongkang First People's Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
- Affiliated Yongkang First People's Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China; Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of Pharmacy,…
- Affiliated Yongkang First People's Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China. Electronic address: zhjingwz@163.com.
Zitieren
APA
Min, J., Zheng, H., Xia, H., Tian, X., Liang, M., Zhang, J., & Huang, W. (2024). Ruxolitinib attenuates microglial inflammatory response by inhibiting NF-κB/MAPK signaling pathway. European Journal of Pharmacology, 968, 176403. https://doi.org/10.1016/j.ejphar.2024.176403
Vancouver
Min J, Zheng H, Xia H, Tian X, Liang M, Zhang J, et al. Ruxolitinib attenuates microglial inflammatory response by inhibiting NF-κB/MAPK signaling pathway. European Journal of Pharmacology. 2024;968:176403. doi:10.1016/j.ejphar.2024.176403
BibTeX
@article{Min2024,
author = {Min, Jingli and Zheng, Hongmei and Xia, Heye and Tian, Xuejun and Liang, Meihao and Zhang, Jing and Huang, Wenhai},
title = {Ruxolitinib attenuates microglial inflammatory response by inhibiting NF-κB/MAPK signaling pathway},
journal = {European Journal of Pharmacology},
year = {2024},
volume = {968},
pages = {176403},
doi = {10.1016/j.ejphar.2024.176403}
}
EUVIMED